Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NKTX
NKARTA, INC.
NASDAQ
$2.92
▲ UP 4.66% (0.13)

KEY STATISTICS

Market Cap$208.55 M
52w High$3.72
52w Low$1.70
Dividend Yield—
Frequency—
P/E-1.86
Volume446.75K
Shares Out.71.55M

COMPANY

LEADERSHIP

Paul J. Hastings
CHIEF EXECUTIVE
Paul J. Hastings

COMPENSATION 2026

Salary$674,384
Stock Awards$236,250
Incentive Plan Pay$344,947
All Other Comp.$10,500
Total$2,978,038

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 10, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
106

PRICE TARGET

Target High$9.00
Target Low$9.00
Target Median$9.00
Target Consensus$9.00

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.—
NOV
10
TUE

PRICE

$2.92 ▲ UP 4.66% (+$0.13)
$2.77$2.85$2.939:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.92

About Nkarta, Inc.

https://www.nkartatx.com ↗

Nkarta, Inc. is a clinical-stage biopharmaceutical company developing NK cell-based immunotherapies for cancer, with lead candidates NKX101 and NKX019 targeting leukemia and B cell malignancies.

INDUSTRY

Biotechnology

A PRODUCT NKARTA, INC. IS KNOWN FOR

NKX019
NKX019

NKX019 is Nkarta's allogeneic, off-the-shelf CAR-NK cell therapy in Phase 1 trials targeting CD19-positive B-cells to treat autoimmune diseases like lupus nephritis.

COMPETITORS

COMPETITOR
ALLO COMPARE
FATE COMPARE
IPSC COMPARE
NKGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
58
LISTED HERE
12
RANKED BY POSITION SIZE
VTI
0.00% · 1.6M
IWM
0.00% · 1.1M
DFAS
0.00% · 145.5K
R2US.L
0.01% · 106.5K
PRFZ
0.01% · 103.0K
AVSC
0.01% · 90.3K
XRS2.DE
0.00% · 40.6K
RSSL
0.00% · 21.2K
URTY
0.00% · 1.8K
FSEV
0.05% · 1.3K
NIFE
0.32% · 882
PQ
PQSG
0.16% · 833

INSTITUTIONAL OWNERSHIP

SHARES OWNED
73.13%
HOLDERS
156
TOP 12 OF 156 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
10.8M sh · $22.8M
Tang Capital Management LLC
7.1M sh · $14.61M
Blackrock, Inc.
4.5M sh · $9.51M
Blackrock Inc.
4.1M sh · $23.99M
Boxer Capital, LLC
4.0M sh · $18.21M
Samsara Biocapital, LLC
3.8M sh · $7.8M
Nea Management Company, LLC
3.6M sh · $7.53M
Sr One Capital Management, LP
3.3M sh · $6.17M
GP
Gsk Plc
3.2M sh · $5.83M
Citadel Advisors LLC
2.9M sh · $6M
Vanguard Group Inc
2.6M sh · $4.81M
Monaco Asset Management Sam
2.5M sh · $4.71M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
HASTINGS PAUL J
Sale · 1.8K shares
2026-06-18
★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 37.0K shares
2026-06-10
★
DIRECTOR
Behbahani Ali
Purchase · 37.0K shares
2026-06-10
★
DIRECTOR
George Simeon
Purchase · 37.0K shares
2026-06-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OUTPERFORM 1
4 GRADES IN THE LAST 12 MONTHS
Stifel BUY HC Wainwright & Co. BUY Needham BUY Mizuho OUTPERFORM

SECTORS PEERS

PEERPRICE
FBRX$76.99COMPARE
VOR$24.91COMPARE
FATE$2.48COMPARE
ALEC$2.52COMPARE
PEPG$3.15COMPARE
MOLN$4.11COMPARE
ELTX$2.43COMPARE